Ribbon Bio Appoints Jay Therrien as Chief Business Officer

VIENNA, Sept. 8, 2026 /CourierPR/ -- Ribbon Bio, a pioneer in cell-free DNA assembly, has appointed Jay Therrien as its Chief Business Officer. This move aims to bolster the company’s commercial strategy and growth initiatives, leveraging Therrien’s extensive experience in the life sciences and genomics sectors.

Therrien brings a wealth of expertise to Ribbon Bio. Previously, he served as Chief Commercial Officer at Ultima Genomics and held executive leadership roles at companies such as IDEX Health & Science, RainDance Technologies, Life Technologies, and Illumina. Throughout his career, he has played a key role in launching several groundbreaking technologies, including multiplex genotyping, digital PCR, and next-generation sequencing platforms. These innovations have supported a wide range of genomic applications across research and clinical markets.

In his new role, Therrien will focus on expanding the adoption of Ribbon Bio’s cell-free DNA solutions. The company’s recently launched MiroMine™ kit is central to this effort. This kit enables customers to access Ribbon Bio’s advanced assembly algorithms and cell-free synthesis processes directly in their own labs. According to Therrien, one of the key benefits of the MiroMine™ kit is its ease of use. He explains, “Using the MiroMine™ kit does not require any unique, single-purpose lab instrumentation or capital equipment. The ability to immediately use the kit in a lab is one of many reasons we expect a rapid adoption of Ribbon’s technology.”

Ribbon Bio’s CEO, Jodi Barrientos, expressed excitement about Therrien’s appointment. “His extensive commercial experience and track record of success will be invaluable as we continue to scale the business and advance our vision for the future of DNA synthesis,” she stated.

Ribbon Bio’s approach to cell-free DNA assembly offers several advantages over traditional plasmid-based methods. By producing DNA independently of bacterial-mediated processes, the company sidesteps limitations such as endotoxin contamination, faster production timelines, and greater reliability at scale. This cell-free approach unlocks new levels of freedom and flexibility, enabling researchers and developers to access DNA molecules of unprecedented length, structure, and complexity.

With the launch of the MiroMine™ kit, Ribbon Bio aims to democratize the use of synthetic DNA, ensuring its place as a foundational tool for next-generation science. The company envisions this technology improving the health of both humanity and the planet.